Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?
Johns Hopkins University · Johns Hopkins Medicine · +3 more institutions
Abstract
Ketamine is a racemic compound and medication comprised of (S)-ketamine and (R)-ketamine enantiomers and its metabolites. It has been used for decades as a dissociative anesthetic, analgesic, and recreational drug. More recently, ketamine, its enantiomers, and its metabolites have been used or are being investigated for the treatment of refractory depression, as well as for comorbid disorders such as anxiety, obsessive-compulsive, and opioid use disorders. Despite its complex pharmacology, ketamine is referred to as an N-methyl-d-aspartate (NMDA) receptor antagonist. In this review, the authors argue that ketamine’s pharmacology should be redefined to include opioid receptors and the endogenous opioid system.…
Citation impact
- FWCI
- 46.50
- Percentile
- 100%
- References
- 150
Authors
6- MRMarjorie R. LevinsteinCorresponding
Johns Hopkins University, Johns Hopkins Medicine, Bellvitge University Hospital, Behavioral Pharma (United States), Stanford University
- RCReece C. Budinich
Johns Hopkins University, Johns Hopkins Medicine, Bellvitge University Hospital, Behavioral Pharma (United States), Stanford University
- JBJordi Bonaventura
Johns Hopkins University, Johns Hopkins Medicine, Bellvitge University Hospital, Behavioral Pharma (United States), Stanford University
- AFAlan F. Schatzberg
Johns Hopkins University, Johns Hopkins Medicine, Bellvitge University Hospital, Behavioral Pharma (United States), Stanford University
- CACarlos A. Zarate
Johns Hopkins University, Johns Hopkins Medicine, Bellvitge University Hospital, Behavioral Pharma (United States), Stanford University
Topics & keywords
- Ketamine
- NMDA receptor
- Pharmacology
- Dissociative
- Opioid
- Analgesic
- Antidepressant
- Opioid receptor
- Zero hunger